Abstract
After nearly a decade of discussion, analysis, and development, the Medicines Adaptive Pathways to Patients (MAPPs) initiative is beginning to see acceptance from regulators, industry, patients, and payers, with the first live pilot project initiated under the guidance of the European Medicines Agency in 2014. Although it is a significant achievement to see the first asset being placed into human trials under an adaptive pathway, there is much to be learned regarding the multinational and multi-stakeholder effort that has driven the growing acceptance of MAPPs as a methodology and concept, as well as the need for continued and increasing international collaboration to foster the wider adoption of MAPPs. Changes in available science and technology, as well as a number of challenges in the current system, outlined in this paper, are transforming approaches to medicines development and approval. It is these challenges that have led directly to the groundbreaking MAPPs collaboration between the Massachusetts Institute of Technology Center for Biomedical Innovation’s New Drug Development Paradigms Initiative, the EMA, patient, payer and health technology assessment groups, the European Federation of Pharmaceutical Industries and Associations, and the Innovative Medicines Initiative—a European public-private partnership. This article examines the development of MAPPs, from inception of the concept, to the establishment of this trans-Atlantic initiative, and examines challenges for the future.
Similar content being viewed by others
References
European Medicines Agency. European Medicines Agency launches adaptive licensing pilot project. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2014/03/WC500163410.pdf. Updated March 19, 2014. Accessed March 25, 2014.
Baird LG, Trusheim M, Eichler HG, et al. Comparison of stakeholder metrics for traditional and adaptive licensing approaches to drug development. Therap Innov Regul Sci. 2013;47;474–483.
Baird LG, Teagarden R., Unger T, Hirsch G. New medicines eight years faster to patients: blazing a new trail in drug development with adaptive licensing. Scrip Regulatory Affairs, May 24, 2013.
Schulthess D. Innovation requires a new regulatory framework to improve research and development of new medical therapies. Health Policy Technol. 2013;4:178–180.
Longly M, Simpson A. New medicine for serious conditions: how patients would weigh the risks and benefits. Genetic Alliance UK. 2014:28.
Horne R, Bell JI, Montgomery JR, et al. A new social contract for medical innovation. Lancet. 2015:385;1153–1154.
The Innovative Medicines Initiative. IMI2 Budget. http://www.imi.europa.eu/content/imi-2#Budget. Accessed November 8, 2014.
Health Canada. Health Products and Food Branch 2007–12 Strategic Plan. http://www.hc-sc.gc.ca/ahc-asc/alt_formats/hpfb-dgpsa/pdf/pubs/strat-plan-2007-2012-eng.pdf. Accessed March 25, 2014.
Health Canada. Progressive licensing. http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/homologation-licensing/plfs_hpfd-eng.pdf. Accessed February 10, 2014.
Institute of Medicine. The future of drug safety: promoting and protecting the health of the public. http://www.iom.edu/reports/2006/the-future-of-drug-safety-promoting-and-protecting-the-health-of-the-public.aspx. Updated September 22, 2006. Accessed February 10, 2014.
European Medicines Agency. Road map to 2015. http://www.ema.europa.eu/docs/en_GB/document_library/Report/2011/01/WC500101373.pdf. Updated December 2010. Accessed February 10, 2014.
Chatham House. Chatham House Rules. http://www.chathamhouse.org/about-us/chathamhouserule. Accessed March 31, 2014.
Baird LG, Banken R, Eichler HG, et al. Accelerated access to innovative medicines for patients in need. Clin. Pharmacol. Ther. 2014:94;464–477.
Tapestry Networks. Pilots of multistakeholder consultations in drug development. http://www.tapestrynetworks.com/initiatives/healthcare/upload/Pilots-of-multi-stakeholder-consultations-in-drug-development-6-June-2012.pdf. Updated June 6, 2012. Accessed March 31, 2014.
Trusheim M, Baird LG, Garner S, Lim R, Patel N, Hirsch G. The Janus initiative: a multi-stakeholder process and tool set for facilitating and quantifying adaptive licensing discussions. Health Policy Technol. 2014:4;241–247.
Vital Transformation. Conference report: new trial pathways and better patient data. vitaltransformation.com/2014/10/conference-report-better-science-better-health-new-trial-pathways-and-better-patient-data/. Updated October 2014. Accessed November 7, 2014
The Pink Sheet. Database exploitation could slash clinical trial durations and cut costs. https://www.pharmamedtechbi.com/publications/the-pink-sheet-daily/2014/10/29/database-exploitation-could-slash-clinical-trial-durations-cut-costs. Accessed November 7, 2014.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schulthess, D., Baird, L.G., Trusheim, M. et al. Medicines Adaptive Pathways to Patients (MAPPs): A Story of International Collaboration Leading to Implementation. Ther Innov Regul Sci 50, 347–354 (2016). https://doi.org/10.1177/2168479015618697
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1177/2168479015618697